Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Clin Cancer Res. 2020 Apr 16;26(13):3248–3258. doi: 10.1158/1078-0432.CCR-19-3313

Figure 1. Combining multiple circulating biomarkers to diagnose and stage PDAC.

Figure 1.

Our biomarker panel consists of the mRNA and miRNA cargo of tumor-derived EVs enriched from plasma, circulating CA19–9, circulating cell-free DNA concentration (as determined by qPCR to detect the ALU repeat element), and circulating mutant KRAS allele fraction. This multiplex panel is combined algorithmically using machine learning. The system is trained using supervised learning on a cohort of 47 patients including 15 healthy individuals, 12 non-cancer disease controls, and 20 with various stages of PDAC. Finally, the developed classifiers are evaluated using an independent, blinded test set of 136 individuals to quantify performance.